{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:29:27Z","timestamp":1707524967864},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,8]]},"DOI":"10.7759\/cureus.35916","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T05:46:12Z","timestamp":1678340772000},"source":"Crossref","is-referenced-by-count":0,"title":["Aetiologies of Acute Complications in Autoimmune Rheumatologic Diseases: A Hospital-Based Cross-Sectional Study"],"prefix":"10.7759","author":[{"given":"Aparna","family":"P","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaibhav","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Singhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Khadanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajnish","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Saigal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin","family":"Kotnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2994-y","article-title":"Rheumatologic emergencies","volume":"34","author":"Guti\u00e9rrez-Gonz\u00e1lez LA","year":"2015","unstructured":"Guti\u00e9rrez-Gonz\u00e1lez LA. Rheumatologic emergencies. Clin Rheumatol. 2015, 34:2011-19. 10.1007\/s10067-015-2994-y","journal-title":"Clin Rheumatol"},{"key":"ref2","article-title":"Emergencies in rheumatology","volume":"101","author":"Kumar A","year":"2003","unstructured":"Kumar A, Marwaha V, Grover R. Emergencies in rheumatology. J Indian Med Assoc. 2003, 101:520, 522, 524 passim.","journal-title":"J Indian Med Assoc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/94.6.309","article-title":"Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice","volume":"94","author":"Grove ML","year":"2001","unstructured":"Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM. 2001, 94:309-19. 10.1093\/qjmed\/94.6.309","journal-title":"QJM"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.5.482","article-title":"Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis","volume":"62","author":"Aletaha D","year":"2003","unstructured":"Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis. 2003, 62:482-6. 10.1136\/ard.62.5.482","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran MF","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002, 46:2287-93. 10.1002\/art.10524","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121075","article-title":"Trends in serious infections in rheumatoid arthritis","volume":"40","author":"Ni Mhuircheartaigh OM","year":"2013","unstructured":"Ni Mhuircheartaigh OM, Matteson EL, Green AB, Crowson CS. Trends in serious infections in rheumatoid arthritis. J Rheumatol. 2013, 40:611-16. 10.3899\/jrheum.121075","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran MF","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002, 46:2294-300. 10.1002\/art.10529","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/art.34530","article-title":"Development and validation of a risk score for serious infection in patients with rheumatoid arthritis","volume":"64","author":"Crowson CS","year":"2012","unstructured":"Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum. 2012, 64:2847-55. 10.1002\/art.34530","journal-title":"Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz T","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006, 295:2275-85. 10.1001\/jama.295.19.2275","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky S","year":"2007","unstructured":"Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007, 46:1157-60. 10.1093\/rheumatology\/kem076","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.002","article-title":"The risk of infections with biologic therapies for rheumatoid arthritis","volume":"39","author":"Furst DE","year":"2010","unstructured":"Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010, 39:327-46. 10.1016\/j.semarthrit.2008.10.002","journal-title":"Semin Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7196\/samj.2015.v105i12.10220","article-title":"Infections in the management of rheumatic diseases: an update","volume":"105","author":"Botha-Scheepers SA","year":"2015","unstructured":"Botha-Scheepers SA, Sarembock B. Infections in the management of rheumatic diseases: an update. S Afr Med J. 2015, 105:1076. 10.7196\/samj.2015.v105i12.10220","journal-title":"S Afr Med J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.55","article-title":"Connective tissue diseases: the burden of serious infections in SLE","volume":"11","author":"Widdifield J","year":"2015","unstructured":"Widdifield J, Bernatsky S. Connective tissue diseases: the burden of serious infections in SLE. Nat Rev Rheumatol. 2015, 11:326-7. 10.1038\/nrrheum.2015.55","journal-title":"Nat Rev Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.39070","article-title":"Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis","volume":"67","author":"Feldman CH","year":"2015","unstructured":"Feldman CH, Hiraki LT, Winkelmayer WC, Marty FM, Franklin JM, Kim SC, Costenbader KH. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. 2015, 67:1577-85. 10.1002\/art.39070","journal-title":"Arthritis Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22575","article-title":"Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996-2011","volume":"67","author":"Tektonidou MG","year":"2015","unstructured":"Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996-2011. Arthritis Care Res (Hoboken). 2015, 67:1078-85. 10.1002\/acr.22575","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen JS","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020, 79:685-99.","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24221","article-title":"Measures of adult systemic lupus erythematosus: disease activity and damage","volume":"72 Suppl 10","author":"Arora S","year":"2020","unstructured":"Arora S, Isenberg DA, Castrejon I. Measures of adult systemic lupus erythematosus: disease activity and damage. Arthritis Care Res (Hoboken). 2020, 72 Suppl 10:27-46. 10.1002\/acr.24221","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.13.24","article-title":"Clinical disease activity assessments in rheumatoid arthritis","volume":"8","author":"Salaffi F","year":"2013","unstructured":"Salaffi F, Ciapetti A. Clinical disease activity assessments in rheumatoid arthritis. Int J Clin Rheumtol. 2013, 8:347-60. 10.2217\/ijr.13.24","journal-title":"Int J Clin Rheumtol"},{"key":"ref19","unstructured":"Rheumatoid Arthritis and Adrenal Function | Dr. James L. Wilson\u2019s AdrenalFatigue.org. (2020). Accessed. July 4: https:\/\/adrenalfatigue.org\/rheumatoid-arthritis\/."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0251","article-title":"Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis","volume":"177","author":"Borresen SW","year":"2017","unstructured":"Borresen SW, Klose M, Baslund B, et al.. Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. Eur J Endocrinol. 2017, 177:287-95. 10.1530\/EJE-17-0251","journal-title":"Eur J Endocrinol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.20329","article-title":"Prognostic accuracy of sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department","volume":"317","author":"Freund Y","year":"2017","unstructured":"Freund Y, Lemachatti N, Krastinova E, et al.. Prognostic accuracy of sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department. JAMA. 2017, 317:301-8. 10.1001\/jama.2016.20329","journal-title":"JAMA"},{"key":"ref22","unstructured":"Goldman\u2019s Cecil Medicine Twenty-Fourth Edition. (2012). Accessed. November 29, 2020: https:\/\/www.sciencedirect.com\/book\/9781437716047\/goldmans-cecil-medicine."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/BF01419946","article-title":"Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India","volume":"16","author":"Shyam C","year":"1996","unstructured":"Shyam C, Malaviya AN. Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India. Rheumatol Int. 1996, 16:1-3. 10.1007\/BF01419946","journal-title":"Rheumatol Int"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/bjaed\/mkw029","article-title":"Rheumatological conditions in critical care","volume":"16","author":"Bell A","year":"2016","unstructured":"Bell A, Tattersall R, Wenham T. Rheumatological conditions in critical care. BJA Educ. 2016, 16:427-33. 10.1093\/bjaed\/mkw029","journal-title":"BJA Educ"},{"key":"ref25","article-title":"Addisonian Crisis","author":"Rathbun KM","year":"2020","unstructured":"Rathbun KM, Nguyen M, Singhal M. Addisonian Crisis. StatPearls [Internet], Treasure Island (FL): StatPearls Publishing; 2020."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70323-7","article-title":"Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis","volume":"13","author":"Wacker C","year":"2013","unstructured":"Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013, 13:426-35. 10.1016\/S1473-3099(12)70323-7","journal-title":"Lancet Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-012-2563-7","article-title":"An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients","volume":"38","author":"Matthaiou DK","year":"2012","unstructured":"Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med. 2012, 38:940-9. 10.1007\/s00134-012-2563-7","journal-title":"Intensive Care Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial","volume":"16","author":"de Jong E","year":"2016","unstructured":"de Jong E, van Oers JA, Beishuizen A, et al.. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016, 16:819-27. 10.1016\/S1473-3099(16)00053-0","journal-title":"Lancet Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/130039-aetiologies-of-acute-complications-in-autoimmune-rheumatologic-diseases-a-hospital-based-cross-sectional-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:02Z","timestamp":1707508262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/130039-aetiologies-of-acute-complications-in-autoimmune-rheumatologic-diseases-a-hospital-based-cross-sectional-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.35916","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,8]]}}}